IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berry, A. M.
Right arrow Articles by Paton, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berry, A. M.
Right arrow Articles by Paton, J. C.

Infection and Immunity, January 2000, p. 133-140, Vol. 68, No. 1
0019-9567/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Additive Attenuation of Virulence of Streptococcus pneumoniae by Mutation of the Genes Encoding Pneumolysin and Other Putative Pneumococcal Virulence Proteins

Anne M. Berry and James C. Paton*

Molecular Microbiology Unit, Women's and Children's Hospital, North Adelaide, South Australia 5006, Australia

Received 2 June 1999/Returned for modification 5 August 1999/Accepted 26 October 1999


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Although the polysaccharide capsule of Streptococcus pneumoniae has been recognized as a sine qua non of virulence, much recent attention has focused on the role of pneumococcal proteins in pathogenesis, particularly in view of their potential as vaccine antigens. The individual contributions of pneumolysin (Ply), the major neuraminidase (NanA), autolysin (LytA), hyaluronidase (Hyl), pneumococcal surface protein A (PspA), and choline-binding protein A (CbpA) have been examined by specifically mutagenizing the respective genes in the pneumococcal chromosome and comparing the impact on virulence in a mouse intraperitoneal challenge model. Mutagenesis of either the ply, lytA, or pspA gene in S. pneumoniae D39 significantly reduced virulence, relative to that of the wild-type strain, indicating that the respective gene products contribute to pathogenesis. On the other hand, mutations in nanA, hyl, or cbpA had no significant impact. The virulence of D39 derivatives carrying a ply deletion mutation as well as an insertion-duplication mutation in one of the other genes was also examined. Mutagenesis of either nanA or lytA did not result in an additional attenuation of virulence in the ply deletion background. However, significant additive attenuation in virulence was observed for the strains with ply-hyl, ply-pspA, and ply-cbpA double mutations.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Streptococcus pneumoniae is an important human pathogen, causing life-threatening invasive diseases such as pneumonia, meningitis and bacteremia, as well as less serious but highly prevalent infections such as otitis media and sinusitis. The high morbidity and mortality associated with pneumococcal disease are exacerbated by the rate at which this organism is acquiring resistance to multiple antibiotics (23). Polyvalent pneumococcal vaccines based on purified capsular polysaccharides have been available for nearly two decades, but their clinical efficacy has been limited by poor immunogenicity in high-risk groups (particularly young children) (16). Furthermore, antipolysaccharide antibodies confer a strictly serotype-specific protection, and only 23 of the 90 known serotypes are covered by existing formulations. The problem of poor vaccine immunogenicity in children is being addressed by conjugation of the polysaccharides to protein carriers. However, serotype coverage will be more limited, as it is unlikely that more than 11 serotypes will be included in such conjugate formulations. In view of this, much recent attention has focused on the possibility of developing vaccines based on pneumococcal protein antigens common to all serotypes (1, 12, 34).

Pneumococcal proteins which contribute to pathogenesis are obvious candidates for inclusion in such vaccines, and of those proteins studied to date, the thiol-activated toxin pneumolysin (Ply) and pneumococcal surface protein A (PspA) are the best characterized (12, 33, 35). Ply is a multifunctional protein having both cytotoxic and complement activation properties (11, 38). It is located in the cytoplasm but is released when pneumococci undergo autolysis (33, 35). PspA is a member of a family of structurally related choline-binding surface proteins (19, 20, 46, 47); its precise function is uncertain, although it has recently been shown to be capable of binding human lactoferrin (21). Both Ply and PspA are protective immunogens, and mutagenesis of the genes which encode them attenuates virulence of S. pneumoniae (1, 3, 7, 9, 10, 12, 13, 31, 45). The major pneumococcal autolysin (LytA) is also a choline-binding protein (19, 20) which contributes to virulence by mediating the release of Ply and possibly also inflammatory cell wall degradation products (4, 9, 26). A further choline-binding protein, CbpA (also referred to as SpsA), has recently been shown to bind the secretory component of secretory IgA (22) and also appears to be an adhesin for cytokine-activated epithelial and endothelial cell lines (39). Pneumococci also produce a hyaluronidase (Hyl) (6) and at least two neuraminidases (NanA and NanB) (5, 14, 27), but the contributions of these to pathogenesis are uncertain (28, 36).

Clearly, development of an effective protein-based vaccine depends on a thorough understanding of the roles of the various putative virulence proteins in pathogenesis, as well as their relative contributions to virulence. Cost considerations will place a limit on the number of different antigens which might be included, and so it is crucial that the most important virulence determinants be covered. In the present study we have compared the virulence of wild-type S. pneumoniae D39 with otherwise isogenic derivatives carrying mutations in the genes encoding Ply, NanA, LytA, Hyl, PspA, or CbpA. The virulence of D39 derivatives carrying a ply deletion mutation as well as an insertion-duplication mutation in one of the other genes was also examined.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Bacterial strains. The virulent type 2 S. pneumoniae strain D39 (NCTC 7466) and its highly transformable, nonencapsulated derivative Rx1 have been described previously (2, 40). Derivatives of D39 with an insertion-duplication mutation in lytA (designated LytA-) or with an in-frame deletion mutation in ply encoding a derivative of Ply lacking amino acids 55 to 437 (designated Delta Ply) have also been described previously (4, 7). The pVA891-directed pspA-negative S. pneumoniae Rx1 derivative WG44-1 (31) was kindly provided by D. E. Briles. Pneumococci were routinely grown in Todd-Hewitt broth with 0.5% yeast extract (THY) or on blood agar. Where appropriate, erythromycin was added to media at a concentration of 0.2 µg/ml.

Escherichia coli K-12 DH5alpha (Bethesda Research Laboratories, Gaithersburg, Md.) was grown in Luria-Bertani broth (30) with or without 1.5% Bacto-agar (Difco Laboratories, Detroit, Mich.). Where appropriate, chloramphenicol or erythromycin was added to the growth medium at a concentration of 25 or 125 µg/ml, respectively.

Transformation. Transformation of E. coli with plasmid DNA was carried out by standard methods with CaCl2-treated cells. S. pneumoniae Rx1 and D39 were transformed with chromosomal or plasmid DNA as described previously (48). Pneumococcal transformants were selected on blood agar containing 0.2 µg of erythromycin per ml.

Southern hybridization analysis. Chromosomal DNA from the various S. pneumoniae D39 derivatives was restricted and electrophoresed on 1.0% agarose gels with a Tris-borate-EDTA buffer system, as described by Maniatis et al. (30). DNA was transferred to nylon membranes (Hybond N+; Amersham, Little Chalfont, Buckinghamshire, England) as described by Southern (41), hybridized to probe DNA, and washed at high stringency, as described by Maniatis et al. (30). Probes specific for the various putative virulence genes were labelled with digoxigenin-11-dUTP (Boehringer Mannheim, Mannheim, Germany), according to the method of Feinberg and Vogelstein (17). The templates used were a 1.2-kb HindIII fragment containing the complete lytA gene (20), a PCR product containing nucleotides (nt) 220 to 1986 of pspA (46), a ClaI/EcoRI fragment comprising nt 1377 to 2786 of hyl (6), an EcoRI/SphI fragment comprising nt 615 to 1803 of nanA (14), and a PCR product comprising nt 481 to 680 of cbpA (22). Washed filters were developed with antidigoxigenin-alkaline phosphatase conjugate and a 4-nitroblue tetrazolium salt (NBT)-5-bromo-4-chloro-3-indolylphosphate (X-phosphate) substrate system (Boehringer Mannheim), according to the manufacturer's instructions.

Virulence factor assays. S. pneumoniae D39 derivatives were grown in THY at 37°C to an A600 of 0.3. Cells from 1 ml of culture were pelleted by centrifugation and lysed by resuspension in 100 µl of a mixture containing phosphate-buffered saline, pH 7.2, and 0.1% sodium deoxycholate. Pneumolysin activity in each lysate was quantitated by a hemolysis assay using human erythrocytes, as described previously (37). Neuraminidase and hyaluronidase were also assayed as previously described, using 2'-(4-methylumbelliferyl)-alpha -D-N-acetylneuraminic acid and umbilical cord hyaluronic acid, respectively, as substrates (6, 27).

Western blot analysis. Proteins in S. pneumoniae lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described by Laemmli (24) and electrophoretically transferred from SDS-PAGE gels onto nitrocellulose filters, as described by Towbin et al. (43). Filters were probed with mouse anti-PspA or mouse anti-LytA (used at a dilution of 1:1,000) followed by goat anti-mouse immunoglobulin G conjugated to alkaline phosphatase (Bio-Rad Laboratories, Richmond, Calif.). Enzyme-labelled bands were visualized with an NBT-X-phosphate substrate system (Boehringer Mannheim).

Virulence studies. S. pneumoniae strains were grown overnight on blood agar (supplemented with erythromycin where appropriate), inoculated into serum broth (meat extract broth plus 10% horse serum), and incubated at 37°C for 3 h. Production of type 2 capsule was confirmed by the Quellung reaction, using antisera obtained from Statens Seruminstitut, Copenhagen, Denmark. Cultures were then diluted in serum broth to the appropriate density, and 0.1-ml volumes were injected intraperitoneally (i.p.) into groups of 12 or 13 BALB/c mice. Survival time was recorded.

Intranasal challenge studies were performed on QS mice which had been anesthetized by i.p. injection with 0.06 mg of sodium pentobarbitone (Nembutal; Boehringer Ingelheim, Sydney, Australia) per g of body weight. Aliquots (50 µl each) of 3-h serum broth cultures of the various S. pneumoniae strains, diluted when appropriate with serum broth to give a density of 108 CFU/ml, were then introduced into the nostrils. Mice regained consciousness after approximately 1 h, and survival time was recorded.

Differences in median survival time between groups were analyzed by the Mann-Whitney U test (two tailed). Differences in the overall survival rate between groups were analyzed by the Fisher exact test.


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Construction and characterization of S. pneumoniae mutants. S. pneumoniae D39 derivatives with insertion-duplication mutations in various genes were constructed by using plasmid pVA891, which encodes chloramphenicol and erythromycin resistance and can replicate in E. coli but not in S. pneumoniae (29). The first step of the mutagenesis procedure involves cloning an internal fragment of the respective gene into pVA891. For nanA, a 637-bp HindIII-SphI fragment corresponding to nt 1210 to 1847 of the nanA open reading frame (ORF) (14) was cloned into HindIII-SphI-digested pVA891. For hyl, a 673-bp ClaI-NcoI fragment corresponding to nt 1286 to 1959 of the hyl ORF (6) was cloned into the ClaI site of pVA891. A 200-bp internal fragment of cbpA, corresponding to nt 481 to 680 of the cbpA ORF (22) was amplified by PCR with primers designed with reference to the cbpA sequence deposited in GenBank (accession no. Y10818), with S. pneumoniae D39 DNA as the template. This was blunt-end ligated into the EcoRV site of pVA891. Each of these constructs was transformed into E. coli DH5alpha .

In a previous study (10) we found that the efficiency of direct transformation of the encapsulated type 2 strain D39 to erythromycin resistance, using recombinant pVA891 derivatives, was very low, even in the presence of exogenous competence factor. Therefore we adopted a two-step approach, initially transforming the highly transformable S. pneumoniae Rx1 with plasmid DNA purified from the various E. coli DH5alpha clones. Chromosomal DNA from representative erythromycin-resistant transformants from each reaction was subjected to Southern hybridization analysis to confirm interruption of the respective gene with the pVA891 sequences, by using probes specific for pVA891 and either nanA, hyl, or cbpA (results not shown). DNA from these derivatives, as well as from the psaA-negative Rx1 derivative WG44-1, was then used to transform the encapsulated parental strain D39, and erythromycin-resistant transformants were isolated from two independent transformation experiments for each interrupted gene. Chromosomal DNA from each of these was subjected to Southern hybridization analysis using probes specific for the respective putative virulence gene or pVA891, to confirm interruption of the respective D39 gene with the vector sequences (Fig. 1). S. pneumoniae D39 transformants with confirmed insertion-duplication mutations in nanA, hyl, pspA, or cbpA were designated NanA-, Hyl-, PspA-, and CbpA-, respectively.


View larger version (68K):
[in this window]
[in a new window]
  		FIG. 1.   Southern hybridization analysis of insertion-duplication mutants. Chromosomal DNA from the indicated S. pneumoniae derivatives was digested with HindIII (for lytA and nanA mutants), EcoRI (for cbpA and hyl mutants), or ClaI (for pspA mutants). Replicate digests were subjected to Southern hybridization analysis using probes specific for the respective virulence factor gene (lytA, cbpA, hyl, pspA, or nanA) and pVA891, as described in Materials and Methods. Lanes: M, prelabelled DNA size marker (bacteriophage SPP1 DNA restricted with EcoRI; sizes from top to bottom are 8.56, 7.43, 6.11, 4.90, 3.64, 2.80, 1.95, 1.88, 1.52, 1.41, and 1.16 kb); P, Delta Ply; L1, LytA-; L2, Delta Ply-LytA-; C1, CbpA-; C2, Delta Ply-CbpA-; H1, Hyl-; H2, Delta Ply-Hyl-; P1, PspA-; P2, Delta Ply-PspA-; N1, NanA-; N2, Delta Ply-NanA-.

Pneumococci with mutations in ply as well as the other genes were constructed by transformation of S. pneumoniae D39 Delta Ply with chromosomal DNA from the various Rx1 derivatives or from S. pneumoniae D39 LytA-. Again, interruption of the respective gene in erythromycin-resistant transformants isolated from two independent transformation experiments was confirmed by Southern hybridization analysis (Fig. 1). Absence of the ply ORF in each of these double mutants was also confirmed by PCR, as previously described (7). S. pneumoniae D39 Delta Ply transformants with confirmed insertion-duplication mutations in nanA, hyl, pspA, lytA, or cbpA were designated Delta Ply-NanA-, Delta Ply-Hyl-, Delta Ply-PspA-, Delta Ply-LytA-, and Delta Ply-CbpA-, respectively.

To confirm that the various single or double mutations did not affect the in vitro growth rate, the S. pneumoniae D39 derivatives were grown overnight on blood agar, inoculated into serum broth, and incubated at 37°C for 5 h. During this period, there was no significant difference in growth rate between any of the mutants and wild-type D39, as judged by viable count (result not shown). To confirm the phenotype of the various S. pneumoniae D39 derivatives, lysates of fresh THY cultures were tested with the hemolysis assay for Ply activity and direct enzyme assays for NanA and Hyl. The pneumolysin titer of the wild-type S. pneumoniae D39 lysate was 2,048 hemolytic units (HU) per ml of culture, but Delta Ply lysates contained <0.2 HU of pneumolysin per ml (the sensitivity limit of the assay). Pneumolysin activity was also undetectable in any of the Delta Ply double mutants. In contrast, all other S. pneumoniae D39 derivatives expressed the wild-type level of pneumolysin activity (2,048 HU/ml). Wild-type D39 and Delta Ply lysates contained 48.7 and 48.9 mU of neuraminidase activity per ml, respectively, but no activity (that is, <0.15 mU/ml) could be detected in lysates of either NanA- or Delta Ply-NanA-. Similarly, D39 and Delta Ply lysates contained 84.8 and 83.6 U of hyaluronidase activity per ml, respectively, but no activity could be detected in lysates of either Hyl- or Delta Ply-Hyl-. Expression of PspA and LytA was assessed by Western blot analysis using polyclonal mouse antisera raised against purified LytA and PspA (anti-CbpA was not available) (Fig. 2). The anti-PspA serum labelled two species in both D39 and Delta Ply lysates with approximate sizes of 75 and 155 kDa, but neither of these species was detectable in lysates of PspA- or Delta Ply-PspA-. The anti-PspA serum used was raised against a 43-kDa N-terminal fragment of PspA purified from recombinant E. coli expressing a truncated pspA gene from S. pneumoniae D39 (47). This fragment does not contain the choline-binding repeat domain common to several pneumococcal surface proteins, and so the presence of two immunoreactive bands is not a consequence of cross-reaction with another protein species. Talkington et al. (42) have previously reported an identical phenomenon with monoclonal anti-PspA for several S. pneumoniae strains including D39. They demonstrated that the low- and high-molecular-weight immunoreactive species corresponded to PspA monomers and noncovalently linked PspA dimers, respectively. The anti-LytA serum labelled a single species of the expected molecular size in both D39 and Delta Ply lysates but not in lysates of LytA- or Delta Ply-LytA- (Fig. 2). With both sera, all the other S. pneumoniae D39 derivatives yielded immunoblot patterns similar to that seen for the wild type (result not shown).


View larger version (36K):
[in this window]
[in a new window]
  		FIG. 2.   Western immunoblot analysis. Lysates of the indicated S. pneumoniae D39 derivatives were separated by SDS-PAGE, electroblotted, and probed with mouse anti-PspA or mouse anti-LytA, as described in the Materials and Methods. Lanes: D, D39; P1, PspA-; P2, Delta Ply-PspA-; Ply, Delta Ply; L1, LytA-; L2, Delta Ply-LytA-. The mobilities of protein size markers are also indicated.

Virulence studies. As an initial comparison of virulence, groups of 12 or 13 BALB/c mice were challenged i.p. with either D39, Delta Ply, NanA-, Hyl-, PspA-, Delta Ply-NanA-, Delta Ply-Hyl-, or Delta Ply-PspA-, at a dose of 103 CFU (Fig. 3). There was no significant difference in either median survival time or overall survival rate between groups challenged with D39, NanA-, and Hyl-. However, both the median survival time and the survival rate for the Delta Ply group were significantly greater than those for the D39 group (P < 0.002 and P < 0.025, respectively). Similarly, both the median survival time and the survival rate for the PspA- group were significantly greater than those for the D39 group (P < 0.002 and P < 0.05, respectively), but they were not significantly different from those for the Delta Ply group. Mice challenged with Delta Ply-NanA- had a median survival time of >21 days and a survival rate of 7 of 12, which was indistinguishable from those for the Delta Ply group (>21 days and 7 of 13). On the other hand, significant increases in survival rate relative to the Delta Ply group were observed in the Delta Ply-Hyl- and Delta Ply-PspA- groups (survival rates were 11 of 12 and 12 of 12, respectively; P < 0.05 and P < 0.025, respectively). The survival rate for the Delta Ply-PspA- group was also significantly higher than the rate of 6 of 12 obtained for the PspA- group (P < 0.025). The difference in survival time between the Delta Ply-PspA- and PspA- groups also reached statistical significance (P < 0.05). Both the median survival time and survival rate for the Delta Ply-Hyl- group (>21 days and 11 of 12) were markedly greater than that for the Hyl- group (1.9 days and 1 of 12) (P < 0.002 and P < 0.001, respectively). In a separate experiment, the i.p. virulence of Delta Ply, LytA-, and Delta Ply-LytA- was compared at a dose of 103 CFU. However, there were no significant differences in either the median survival times or survival rates between any of these groups (result not presented).


View larger version (17K):
[in this window]
[in a new window]
  		FIG. 3.   Survival times of mice after i.p. challenge. Groups of 12 or 13 BALB/c mice were injected i.p. with approximately 103 CFU of the indicated strains. Each datum point represents one mouse. The horizontal lines denote the median survival time for each group.

When the comparative virulence of the various strains tested above was assessed at a higher i.p. dose (105 CFU), essentially similar results were obtained (Fig. 4). However, at this dose, a significant difference in virulence between D39 and PspA- was not detectable. Of the various D39 derivatives with mutations in a single gene, only Delta Ply had a significantly greater survival time and higher survival rate than the wild-type strain (P < 0.002 and P < 0.025, respectively). LytA- was also significantly less virulent than D39 as judged by survival time (P <0.05), but the survival rate was not significantly greater. Again, the double mutant Delta Ply-Hyl- was less virulent than Delta Ply, as judged by both survival time and survival rate (P < 0.05 and P < 0.05, respectively). Delta Ply-PspA- was also less virulent that PspA- as judged by both survival time and survival rate (P < 0.002 and P < 0.025, respectively). However, the difference in median survival time between the Delta Ply-PspA- group (>21 days) and the Delta Ply group (5.9 days) did not quite reach statistical significance (0.05 < P < 0.1). Furthermore, there was no significant difference in the virulence of Delta Ply, LytA-, and Delta Ply-LytA-.


View larger version (20K):
[in this window]
[in a new window]
  		FIG. 4.   Survival times of mice after i.p. challenge. Groups of 12 BALB/c mice were injected i.p. with approximately 105 CFU of the indicated strains. Each datum point represents one mouse. The horizontal lines denote the median survival time for each group.

In the second series of experiments, the virulence of D39, Delta Ply, PspA-, CbpA-, Delta Ply-PspA-, and Delta Ply-CbpA- was compared by challenging groups of 12 mice i.p., initially at a dose of 5 × 103 CFU (Fig. 5). Of the D39 derivatives with single mutations, Delta Ply was the least virulent; both survival time and survival rate were significantly greater than those for either PspA- (P < 0.002 and P < 0.025, respectively), CbpA- (P < 0.002 and P < 0.005, respectively), and D39 (P < 0.002 and P < 0.005, respectively). The median survival time for the PspA group was significantly different from that for the D39 group (P < 0.05), but there was no significant difference in survival rate. However, there was no significant difference in the virulence of CbpA- and D39 as judged by either criterion. Although the overall survival rates for the groups challenged with Delta Ply-PspA- or Delta Ply-CbpA- (11 of 12 and 12 of 12, respectively) were numerically greater than that for the Delta Ply group (8 of 12), this was not statistically significant. Accordingly, the i.p. challenge dose was increased to 8 × 106 CFU of each strain (Fig. 6). At this dose, none of the mice challenged with D39 or D39 derivatives with single mutations survived. However, the median survival times for the Delta Ply and PspA- groups (1.75 and 1.12 days, respectively) were significantly different from that for the D39 group (<0.75 days) (P < 0.002 in both cases). The median survival time for the CbpA- group (<0.75 days) was indistinguishable from that for the D39 group. The differences in median survival time between the Delta Ply group and either the PspA- or CbpA- group were also significant (P < 0.002 in both cases). The D39 derivatives with double mutations, Delta Ply-PspA- and Delta Ply-CbpA-, were significantly less virulent than either D39 or any of the single mutants, as judged by both median survival time (P < 0.002, except for Delta Ply-CbpA- versus Delta Ply, for which P is <0.02), and survival rate (P < 0.005).


View larger version (15K):
[in this window]
[in a new window]
  		FIG. 5.   Survival times of mice after i.p. challenge. Groups of 12 BALB/c mice were injected i.p. with approximately 5 × 103 CFU of the indicated strains. Each datum point represents one mouse. The horizontal lines denote the median survival time for each group.


View larger version (15K):
[in this window]
[in a new window]
  		FIG. 6.   Survival times of mice after i.p. challenge. Groups of 12 BALB/c mice were injected i.p. with approximately 8 × 106 CFU of the indicated strains. Each datum point represents one mouse. The horizontal lines denote the median survival time for each group.

As confirmation of these findings, additional Delta Ply-PspA-, Delta Ply-CbpA-, and Delta Ply-Hyl- mutants were isolated as described above, but from independent transformation experiments. The virulence of these independent mutants was then compared with that of Delta Ply, and with that of the original Delta Ply-PspA-, Delta Ply-CbpA-, and Delta Ply-Hyl- mutants, by i.p. challenge at a dose of approximately 105 CFU. The virulence of these mutants relative to that of Delta Ply was essentially as reported above, and there was no significant difference in either median survival time or overall survival rate between the respective pairs of independent mutants (results not presented).

In view of the previous report that CbpA may be an adhesin for cytokine-activated lung cells and that cbpA mutants have diminished capacity to colonize the nasopharynx of infant rats (39), virulence studies were also carried out with a mouse intranasal challenge model (Fig. 7). Both Delta Ply and PspA- were less virulent than D39, as judged by median survival time (P < 0.02 in both cases). The survival rate of the PspA- group was also significantly greater than that of the D39 group (P < 0.05). However, the intranasal virulence of CbpA- was not significantly different from that of D39, as judged by either survival time or survival rate. Nevertheless, the Delta Ply-CbpA- group survived significantly longer than the Delta Ply group (P < 0.05) and the CbpA- group (P < 0.002). Both the median survival time and the survival rate of the Delta Ply-PspA- group were significantly greater than those of the Delta Ply group (P < 0.002 and P < 0.01, respectively). However, although both the survival time and survival rate of the Delta Ply-PspA- group (>21 days and 9 of 12) were numerically greater than those of the PspA- group (6.8 days and 6 of 12), these differences did not reach statistical significance.


View larger version (15K):
[in this window]
[in a new window]
  		FIG. 7.   Survival times of mice after intranasal challenge. Groups of 12 QS mice were anesthetized and challenged intranasally with approximately 5 × 106 CFU of the indicated strains. Each datum point represents one mouse. The horizontal lines denote the median survival time for each group.


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Although it has been known for a number of years that mutations in genes encoding Ply, PspA, and LytA reduce the virulence of S. pneumoniae (4, 10, 31), comparatively little is known of the impact of mutations in genes encoding other putative virulence factors. With the exception of a comparison of lytA and ply mutations in a type 3 pneumococcus (9), no previous studies have directly compared the virulence of strains with single mutations in the various virulence factor genes. Moreover, the impact of mutations in multiple virulence factor genes has not been examined before. In the present study, we have shown that S. pneumoniae D39 derivatives with either a deletion mutation in ply (Delta Ply) or insertion-duplication mutations in lytA (LytA-) or pspA (PspA-) had significantly lower virulence for mice than did wild-type D39, as judged by both survival time and survival rate after i.p. challenge. In the i.p. model, the impact of the ply mutation was quantitatively greater than the pspA mutation, since when higher doses were tested, Delta Ply was significantly less virulent than PspA-. However, the virulence of Delta Ply was not significantly different from that of LytA-. In contrast, mutations in nanA, hyl, or cbpA did not result in detectable reduction in i.p. virulence. The effects on virulence observed for the various insertion-duplication mutants are not attributable to polar effects on downstream sequences, because in each case, strong transcription termination signals are located immediately 3' to the interrupted gene.

When the impact of combinations of the ply and other mutations was examined, a D39 derivative deficient in production of both Ply and NanA was no less virulent than the strain carrying the ply mutation on its own. The single mutant NanA- was also fully virulent, suggesting that this neuraminidase plays a minimal role in the pathogenesis of pneumococcal sepsis. This is essentially in accordance with our previous finding that immunization with purified NanA confers only very weak protection against challenge with wild-type D39, and immunization with NanA and Ply provided no more protection than that achieved by immunization with Ply alone (28). The interpretation of both these findings is complicated to some extent by the fact that S. pneumoniae produces at least one other functional neuraminidase, NanB (5), which may have compensated for the absence or neutralization of NanA. Examination of the partial S. pneumoniae type 4 genome sequence (available at ftp://ftp.tigr.org/pub/data/s_pneumoniae/) also indicates the presence of an ORF on contig SP34 (designated nanC) which encodes a polypeptide with the structural features of a neuraminidase exhibiting approximately 50% deduced amino acid sequence identity to NanB. However, we have previously shown that the specific activity of NanA is much greater than NanB, and NanB also has a significantly lower pH optimum (5). When assayed at physiological pH with the fluorogenic substrate 2'-(4-methylumbelliferyl)-alpha -D-N-acetylneuraminic acid, lysates of NanA- exhibited less than 0.3% of the neuraminidase activity of D39 (result not presented). Of course, it remains a possibility that the specific activity of NanB (and perhaps also NanC) may be higher with natural substrates, or that the expression of either nanB or nanC is specifically up-regulated in vivo. We are currently attempting to construct D39 derivatives with mutations in all three neuraminidase-encoding genes in order to resolve the remaining uncertainties concerning the role of these enzymes in pathogenesis of pneumococcal disease.

The D39 derivative deficient in production of both Ply and LytA was no less virulent than strains carrying either mutation on its own. We have previously demonstrated that although purified Ply and LytA were protective immunogens in mice against challenge with virulent pneumococci, no additive protection occurred when mice were immunized with both antigens (26). Furthermore, immunization with LytA provided no protection whatsoever against challenge with a Ply-negative pneumococcus. This suggested that the principal role of LytA in pathogenesis of invasive pneumococcal disease (at least in the i.p. challenge model) was to mediate release of Ply from the cells in vivo (26). This led us to predict that mutagenizing both ply and lytA would not result in additive attenuation of virulence; this prediction was upheld by the findings of the present study.

In contrast to the results above, the double mutants Delta Ply-Hyl-, Delta Ply-CbpA-, and Delta Ply-PspA- were all significantly less virulent than any of the D39 derivatives with single mutations. This was unexpected for Delta Ply-Hyl- and Delta Ply-CbpA-, because the single mutants Hyl- and CbpA- appeared to be as virulent as D39, even at the lowest dose tested. The additional attenuation of virulence achieved by mutagenizing two virulence factor genes was very considerable indeed. At the maximum i.p. dose tested (8 × 106 CFU), the survival rates for mice challenged with Delta Ply-CbpA- and Delta Ply-PspA- were 67 and 75%, respectively. The i.p. 50% lethal dose of wild-type D39 in this strain of mice is <102 CFU. Thus, mutagenesis of either of these pairs of virulence genes resulted in at least a 105-fold increase in 50% lethal dose. Such a massive impact on virulence has been observed previously only by transposon mutagenesis of S. pneumoniae genes essential for polysaccharide capsule production (44) or insertion-duplication mutagenesis of psaA (8), which encodes a permease with specificity for Mn2+ (15) and possibly also Zn2+ (25). However, mutagenesis of psaA has recently been reported to have pleiotropic effects, including reduced expression of CbpA and other potentially important choline-binding surface proteins (32).

In a previous study, Rosenow et al. (39) demonstrated that CbpA-deficient pneumococci exhibit a reduced capacity to colonize the nasopharynges of infant rats, but there was no apparent impact on virulence in a model of sepsis. While our findings for CbpA- are consistent with the latter result, the additional attenuation of virulence of Delta Ply-CbpA- with respect to Delta Ply clearly indicates that CbpA plays a measurable role in pathogenesis of systemic disease. This is consistent with the finding that this protein is an adhesin for cytokine-activated epithelial and endothelial cells (39). The apparent involvement of CbpA in nasopharyngeal colonization also prompted us to examine the virulence of the various mutants in an intranasal challenge model. One would predict that cbpA mutations would have a more significant impact on virulence in models such as this, which require the pneumococcus to penetrate the respiratory mucosa. However, these studies yielded findings analogous to those obtained with the i.p. challenge model; CbpA- had virulence similar to that of D39, but Delta Ply-CbpA- was significantly less virulent than either Delta Ply or CbpA-.

The additive attenuation of virulence observed by mutagenizing ply as well as either pspA, hyl, or cbpA indicates that Ply and the other virulence proteins have independent functions in the pathogenesis of systemic pneumococcal disease. It follows from this that if the biological functions of these proteins can be blocked by antibody, then immunization with combinations of Ply and either Hyl, PspA, or CbpA might provide a higher degree of protection against S. pneumoniae than immunization with Ply alone. Ply has previously been shown to provide a significant degree of protection against multiple serotypes of S. pneumoniae (1). This protection is presumably due to neutralization of free toxin released from the pneumococcus by autolysis, and anti-Ply antibodies would not be expected to promote opsonophagocytic clearance. In contrast, antibodies directed against surface proteins might be expected to result in opsonization if they are not obscured by the polysaccharide capsule. In fresh S. pneumoniae cultures, most of the Hyl activity is cell associated (6), which is consistent with the presence of the gram-positive cell surface anchorage domain (LPXTGE) (18) near its C terminus. However, to date we have not been able to demonstrate any protection in a mouse model, using purified Hyl as the immunogen (36). The N-terminal portion of the choline-binding protein PspA has been predicted to have a coiled-coil structure reminiscent of the M proteins of group A streptococci (46), and this might be expected to protrude through the capsule. Although the N-terminal region is highly variable, PspA contains conserved epitopes which elicit antibodies protective against multiple S. pneumoniae serotypes (13, 45). CbpA is structurally similar to PspA; the C-terminal choline-binding domains have >90% amino acid sequence identity, and although there is no sequence similarity, the N-terminal portion of CbpA is also predicted to have a coiled-coil structure (22, 39). Like PspA, the N-terminal region of CbpA is highly variable, and it is not yet known whether this region contains common epitopes capable of eliciting protection against challenge with heterologous S. pneumoniae strains. Notwithstanding this uncertainty, examination of the protective efficacy of immunization with a combination of Ply and either PspA or CbpA is clearly warranted.


    ACKNOWLEDGMENT

This work was supported by a grant from the National Health and Medical Research Council of Australia.


    FOOTNOTES

* Corresponding author. Mailing address: Molecular Microbiology Unit, Women's and Children's Hospital, North Adelaide, S.A. 5006, Australia. Phone: 61-8-8204 6302. Fax: 61-8-8204 6051. E-mail: patonj{at}wch.sa.gov.au.

Editor:   V. A. Fischetti


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Alexander, J. E., R. A. Lock, C. C. A. M. Peeters, J. T. Poolman, P. W. Andrew, T. J. Mitchell, D. Hansman, and J. C. Paton. 1994. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect. Immun. 62:5683-5688[Abstract/Free Full Text].
2. Avery, O. T., C. M. MacLeod, and M. McCarty. 1944. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J. Exp. Med. 79:137-158[Abstract].
3. Berry, A. M., J. E. Alexander, T. J. Mitchell, P. W. Andrew, D. Hansman, and J. C. Paton. 1995. Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect. Immun. 63:1969-1974[Abstract].
4. Berry, A. M., R. A. Lock, D. Hansman, and J. C. Paton. 1989. Contribution of autolysin to the virulence of Streptococcus pneumoniae. Infect. Immun. 57:2324-2330[Abstract/Free Full Text].
5. Berry, A. M., R. A. Lock, and J. C. Paton. 1996. Cloning and characterization of nanB, a second Streptococcus pneumoniae neuraminidase gene, and purification of the NanB enzyme from recombinant Escherichia coli. J. Bacteriol. 178:4854-4860[Abstract/Free Full Text].
6. Berry, A. M., R. A. Lock, S. M. Thomas, D. P. Rajan, D. Hansman, and J. C. Paton. 1994. Cloning and nucleotide sequence of the Streptococcus pneumoniae hyaluronidase gene and purification of the enzyme from recombinant Escherichia coli. Infect. Immun. 62:1101-1108[Abstract/Free Full Text].
7. Berry, A. M., A. D. Ogunniyi, D. C. Miller, and J. C. Paton. 1999. Comparative virulence of Streptococcus pneumoniae strains with insertion-duplication, point, and deletion mutations in the pneumolysin gene. Infect. Immun. 67:981-985[Abstract/Free Full Text].
8. Berry, A. M., and J. C. Paton. 1996. Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect. Immun. 64:5255-5262[Abstract].
9. Berry, A. M., J. C. Paton, and D. Hansman. 1992. Effect of insertional inactivation of the genes encoding pneumolysin and autolysin on the virulence of Streptococcus pneumoniae type 3. Microb. Pathog. 12:87-93[CrossRef][Medline].
10. Berry, A. M., J. Yother, D. E. Briles, D. Hansman, and J. C. Paton. 1989. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect. Immun. 57:2037-2042[Abstract/Free Full Text].
11. Boulnois, G. J., J. C. Paton, T. J. Mitchell, and P. W. Andrew. 1991. Structure and function of pneumolysin, the multifunctional, thiol-activated toxin of Streptococcus pneumoniae. Mol. Microbiol. 5:2611-2616[CrossRef][Medline].
12. Briles, D. E., R. C. Tart, E. Swiatlo, J. P. Dillard, P. Smith, K. A. Benton, B. A. Ralph, A. Brooks-Walter, M. J. Crain, S. K. Hollingshead, and L. S. McDaniel. 1998. Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin. Microbiol. Rev. 11:645-657[Abstract/Free Full Text].
13. Briles, D. E., R. C. Tart, H. Y. Wu, B. A. Ralph, M. W. Russell, and L. S. McDaniel. 1998. Systemic and mucosal protective immunity to pneumococcal surface protein A. Ann. N. Y. Acad. Sci. 797:118-126[Abstract].
14. Camara, M., G. J. Boulnois, P. W. Andrew, and T. J. Mitchell. 1994. A neuraminidase from Streptococcus pneumoniae has the features of a surface protein. Infect. Immun. 62:3688-3695[Abstract/Free Full Text].
15. Dintilhac, A., G. Alloing, C. Granadel, and J.-P. Claverys. 1997. Competence and virulence of Streptococcus pneumoniae: Adc and PsaA mutants exhibit a requirement for Zn and Mn resulting from inactivation of putative ABC metal permeases. Mol. Microbiol. 25:727-739[CrossRef][Medline].
16. Douglas, R. M., J. C. Paton, S. J. Duncan, and D. Hansman. 1983. Antibody response to pneumococcal vaccination in children younger than five years of age. J. Infect. Dis. 148:131-137[Medline].
17. Feinberg, A. P., and B. Vogelstein. 1983. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:6-13[CrossRef][Medline].
18. Fischetti, V. A., V. Pancholi, and O. Schneewind. 1990. Conservation of a hexapeptide sequence in the anchor regions of surface proteins from gram-positive cocci. Mol. Microbiol. 4:1603-1605[Medline].
19. García, E., J. L. García, P. García, A. Arraras, M. Sanchez-Puelles, and R. López. 1988. Molecular evolution of lytic enzymes of Streptococcus pneumoniae and its bacteriophages. Proc. Natl. Acad. Sci. USA 85:914-918[Abstract/Free Full Text].
20. García, P., J. L. García, E. García, and R. López. 1986. Nucleotide sequence and expression of the pneumococcal autolysin gene from its own promoter in Escherichia coli. Gene 43:265-272[CrossRef][Medline].
21. Hammerschmidt, S., G. Bethe, P. H. Remane, and G. S. Chhatwal. 1999. Identification of pneumococcal surface protein A as a lactoferrin-binding protein of Streptococcus pneumoniae. Infect. Immun. 67:1683-1687[Abstract/Free Full Text].
22. Hammerschmidt, S., S. R. Talay, P. Brandtzaeg, and G. S. Chhatwal. 1997. SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol. Microbiol. 25:1113-1124[CrossRef][Medline].
23. Klugman, K. P. 1990. Pneumococcal resistance to antibiotics. Clin. Microbiol. Rev. 3:171-196[Abstract/Free Full Text].
24. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685[CrossRef][Medline].
25. Lawrence, M. C., P. A. Pilling, A. D. Ogunniyi, A. M. Berry, and J. C. Paton. 1998. Crystal structure of pneumococcal surface antigen PsaA. Structure 6:1553-1561[Medline].
26. Lock, R. A., D. Hansman, and J. C. Paton. 1992. Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae. Microb. Pathog. 12:137-143[CrossRef][Medline].
27. Lock, R. A., J. C. Paton, and D. Hansman. 1988. Purification and immunological characterization of neuraminidase produced by Streptococcus pneumoniae. Microb. Pathog. 4:33-43[CrossRef][Medline].
28. Lock, R. A., J. C. Paton, and D. Hansman. 1988. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae infection. Microb. Pathog. 5:461-467[CrossRef][Medline].
29. Macrina, F. L., R. P. Evans, J. A. Tobian, D. L. Hartley, D. B. Clewell, and K. R. Jones. 1983. Novel shuttle plasmid vehicles for Escherichia-Streptococcus transgeneric cloning. Gene 25:145-150[CrossRef][Medline].
30. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
31. McDaniel, L. S., J. Yother, M. Vijayakamur, L. McGarry, W. R. Guild, and D. E. Briles. 1987. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J. Exp. Med. 165:381-394[Abstract/Free Full Text].
32. Novak, R., J. S. Braun, E. Charpentier, and E. Tuomanen. 1998. Penicillin tolerance genes of Streptococcus pneumoniae: the ABC-type manganese permease complex PsaA. Mol. Microbiol. 29:1285-1296[CrossRef][Medline].
33. Paton, J. C. 1996. The contribution of pneumolysin to the pathogenicity of Streptococcus pneumoniae. Trends Microbiol. 4:103-106[CrossRef][Medline].
34. Paton, J. C. 1998. Novel pneumococcal surface proteins: role in virulence and vaccine potential. Trends Microbiol. 6:85-87[CrossRef][Medline].
35. Paton, J. C., P. W. Andrew, G. J. Boulnois, and T. J. Mitchell. 1993. Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins. Annu. Rev. Microbiol. 47:89-115[Medline].
36. Paton, J. C., A. M. Berry, and R. A. Lock. 1997. Molecular analysis of putative pneumococcal virulence proteins. Microb. Drug Resist. 3:1-10[Medline].
37. Paton, J. C., R. A. Lock, and D. Hansman. 1983. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect. Immun. 40:548-552[Abstract/Free Full Text].
38. Paton, J. C., B. Rowan-Kelly, and A. Ferrante. 1984. Activation of human complement by the pneumococcal toxin, pneumolysin. Infect. Immun. 43:1085-1087[Abstract/Free Full Text].
39. Rosenow, C., P. Ryan, J. N. Weiser, S. Johnson, P. Fontan, A. Ortqvist, and H. R. Masure. 1997. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol. Microbiol. 25:819-829[CrossRef][Medline].
40. Shoemaker, N. B., and W. R. Guild. 1974. Destruction of low efficacy markers is a slow process occurring at a heteroduplex stage of transformation. Mol. Gen. Genet. 128:283-290[CrossRef][Medline].
41. Southern, E. M. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503-517[CrossRef][Medline].
42. Talkington, D. F., D. C. Voellinger, L. S. McDaniel, and D. E. Briles. 1992. Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membrane. Microb. Pathog. 13:343-355[CrossRef][Medline].
43. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-4354[Abstract/Free Full Text].
44. Watson, D. A., and D. M. Musher. 1990. Interruption of capsule production in Streptococcus pneumoniae serotype 3 by insertion of transposon Tn916. Infect. Immun. 58:3135-3138[Abstract/Free Full Text].
45. Wu, H. Y., M. H. Nahm, Y. Guo, M. W. Russell, and D. E. Briles. 1997. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 175:839-846[Medline].
46. Yother, J., and D. E. Briles. 1992. Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J. Bacteriol. 174:601-609[Abstract/Free Full Text].
47. Yother, J., G. L. Handsome, and D. E. Briles. 1992. Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J. Bacteriol. 174:610-618[Abstract/Free Full Text].
48. Yother, J., L. S. McDaniel, and D. E. Briles. 1986. Transformation of encapsulated Streptococcus pneumoniae. J. Bacteriol. 168:1463-1465[Abstract/Free Full Text].

Infection and Immunity, January 2000, p. 133-140, Vol. 68, No. 1
0019-9567/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles: